侯鹏，男，1974年，西安交通大学第九批“腾飞”特聘教授及第一批“青年拔尖人才”，内分泌科副主任，博士生导师。2004年毕业于东南大学生物医学工程学院，获得博士学位。2005年至2009年在美国约翰·霍普金斯大学医学院内分泌新陈代谢科从事博士后研究。2009年9月受聘西安交通大学医学院第一附属医院内分泌科，并获得光华基金资助，次年获得教育部新世纪人才支持计划。目前为中华医学会内分泌学分会第九届委员会青年委员会委员、中华医学会陕西省内分泌分会委员、中华医学会内分泌分会“转化医学学组”成员、中国细胞生物学会青年委员会委员、陕西省抗癌协会生物样本库专业委员会常务委员、国家自然科学基金重点及面上项目一审专家、国际杂志 《Am J Cancer Res.; 影响因子：4.165》 及 《World Journal of Gastroenterology; 影响因子：2.369》 编委。课题组先后获得国家自然科学基金8项，973子项目1项，教育部博士点基金（博导类）1项及其它多项基金资助。近年来，申请者共发表SCI论文80余篇，ISI引用次数为1429，H指数为21，其中以第一作者及通讯作者发表SCI论文50篇，影响因子大于5的SCI论文22篇，影响因子总计超过240。
代表论文（*通讯作者）
1) Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216-8. (IF: 10.431)
2) Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003; 31(16):e92. (IF: 9.112)
3) Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M*. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. (IF: 8.722)
4) Hou P*, Chen Z, Ji M, He N, Lu Z*. Real-time PCR assay for ultrasensitive quantification of DNA-binding proteins. Clin Chem. 2007; 53(4):581-6. (IF: 7.911)
5) Hou P, Ji M, Li S, Lu Z*. Microarray-based approach for high-throughput genotyping of single-nucleotide polymorphisms with layer-by-layer dual-color fluorescence hybridization. Clin Chem. 2004; 50(10):1955-7. (IF: 7.911)
6) Shi J, Liu W, Sui F, Lu R, He Q, Yang Q Lv H, Shi B, Hou P*. Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer. Oncotarget 2015 Apr 29 (IF: 6.359)
7) Wang L, Tian L, Yang Q, Li H, Guan H, Shi B, Hou P*. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget. 2015 (In press) (IF: 6.359)
8) Qiang W, Zhao Y, Yang Q, Liu W, Guan H, Lv S, Ji M, Shi B, Hou P*. ZIC1 Is a Putative Tumor Suppressor in Thyroid Cancer by Modulating Major Signaling Pathways and Transcription Factor FOXO3a. J Clin Endocrinol Metab. 2014; 99(7):E1163-72. (IF: 6.209)
9) Cui B, Yang Q, Guan H, Shi B, Hou P*, Ji M. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 6.209)
10) Yang Q, Ji M, Guan H, Shi B, Hou P*. Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness through Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2013; 98(12):E1909-17. (IF: 6.209)
11) Hou P, Bojdani E, Xing M*. Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2010; 95(2):820-8. (IF: 6.209)
12) Wang Y#, Hou P#, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M*. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007; 92(6):2387-90. (IF: 6.209) #并列第一作者
其它SCI论文请链接 http://www.ncbi.nlm.nih.gov/pubmed/?term=peng+hou
